Orexo has developed from being an R&D stage company to becoming a profitable fully integrated specialty pharmaceutical company with its own commercial business in the US. From a strong operational and financial platform, Orexo is aiming to become a leader in the field of addiction. To achieve this, the commercial business will be broadened through business development, M&A and launch of ­proprietary pharmaceuticals and digital therapies.

Objectives and strategies 2020 and onwards

 

1. Broaden the portfolio of commercial products to be promoted by our US organization

2. Maintain ZUBSOLV® profit contribution in 2020 and ensure it is sustainable and growing over time

3. Establish a new revenue generating business area within Digital Therapeutics and launch the first new product in 2020

4. Launch a new product from the pharmaceutical pipeline within the next two years